Repligen Corporation (NASDAQ:RGEN) Receives $165.00 Consensus Target Price from Brokerages

Shares of Repligen Corporation (NASDAQ:RGEN) have earned a consensus rating of “Moderate Buy” from the seventeen brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, twelve have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $165.3571.

A number of equities analysts have commented on the stock. Royal Bank Of Canada initiated coverage on shares of Repligen in a report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 target price for the company. Jefferies Financial Group reaffirmed a “hold” rating and issued a $142.00 price objective on shares of Repligen in a research report on Tuesday, May 5th. Benchmark upgraded shares of Repligen from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a research note on Tuesday, July 7th. Barclays increased their target price on shares of Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Finally, Citigroup upgraded shares of Repligen to a “buy” rating in a research note on Tuesday, July 7th.

Insider Transactions at Repligen

In other Repligen news, CFO Jason K. Garland sold 733 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the sale, the chief financial officer directly owned 19,359 shares in the company, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Repligen

Several hedge funds have recently modified their holdings of the stock. Wasatch Advisors LP raised its position in shares of Repligen by 27.9% in the 2nd quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock valued at $216,974,000 after purchasing an additional 346,720 shares during the last quarter. Handelsbanken Fonder AB grew its position in Repligen by 11.8% during the 2nd quarter. Handelsbanken Fonder AB now owns 22,070 shares of the biotechnology company’s stock worth $3,011,000 after purchasing an additional 2,332 shares during the last quarter. Everhart Financial Group Inc. purchased a new stake in Repligen during the 2nd quarter worth approximately $303,000. Assenagon Asset Management S.A. acquired a new position in Repligen during the 2nd quarter valued at approximately $9,687,000. Finally, Balefire LLC acquired a new position in Repligen during the 2nd quarter valued at approximately $275,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Trending Headlines about Repligen

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Repligen agreed to buy BioLife Solutions in a cash-and-stock transaction valued at about $1.5 billion, adding BioLife’s biopreservation media and cell processing tools to Repligen’s portfolio and broadening its exposure to cell therapy. Article Title
• Positive Sentiment: Management said the deal should be accretive to revenue growth, margins, and adjusted EPS, with at least $20 million of synergies in year one and $30 million in year two, which supports the investment case for long-term earnings growth. Article Title
• Neutral Sentiment: The purchase price includes both cash and Repligen shares, so while the acquisition could create growth opportunities, investors may also be weighing potential dilution and integration risk until the deal closes, which is expected in Q4 2026. Article Title
• Negative Sentiment: Some commentary suggests the market may be cautious on the acquisition price and deal structure, with one analyst note on BioLife saying the transaction caps upside, reflecting some skepticism around valuation and near-term execution. Article Title

Repligen Trading Up 2.3%

Shares of NASDAQ:RGEN opened at $140.09 on Thursday. Repligen has a 12-month low of $100.99 and a 12-month high of $175.77. The business’s fifty day simple moving average is $130.41 and its 200-day simple moving average is $132.79. The company has a market capitalization of $7.90 billion, a PE ratio of 155.66, a P/E/G ratio of 2.64 and a beta of 1.06. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The firm had revenue of $194.25 million during the quarter, compared to analysts’ expectations of $192.05 million. During the same period in the prior year, the business posted $0.39 EPS. The firm’s quarterly revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, equities research analysts predict that Repligen will post 1.99 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.